Rima Al‐awar - Concepedia

Author

Rima Al‐awar

Ontario Institute for Cancer Research ORCID

Also Known As

Al-Awar, Rima, Al-awar, Rima, R Al-Awar, R Al-awar, R. Al-Awar, R. Al-awar, R. S. AL‐AWAR, R. S. Al-awar, R. al-Awar, R.S. Al-awar

251

Publications

5.8K

Citations

H-Index

Concepts

All Affiliations

Ontario Institute for Cancer Research University of Toronto Princess Margaret Cancer Centre Structural Genomics Consortium University Health Network

About

Rima Al‐awar is an author at Ontario Institute for Cancer Research specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	28	2.8K
2	Natural Sciences	12	12	1.1K
3	Engineering	9	9	373
4	Biochemistry	8	8	725
5	Health Sciences	4	4	555

Rima Al‐awar

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth Jiajun Zhu, Morgan A. Sammons, Greg Donahue, Nature Cancer ResearchChromatinChromatin RemodelingMedicineCancer Growth	2015	482
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia Alicia M. Cole, Zezhou Wang, Étienne Coyaud, Cancer Cell Hematological MalignancyMitochondrial FunctionMitochondrial Protease ClppMedicineMalignant Blood Disorder	2015	340
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors Wenyu Yu, Emma J. Chory, Amy K. Wernimont, Nature Communications BiochemistryNatural SciencesBiocatalysisCatalytic Site RemodellingEnzyme Catalysis	2012	283
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia Florian Grebien, Masoud Vedadi, Matthäus Getlik, Nature Chemical Biology Hematological MalignancyMedicinePharmacologyCancer BiologyCell Biology	2015	282
( <i>R</i> )-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells Dalia Baršytė-Lovejoy, Fengling Li, Menno J. Oudhoff, Proceedings of the National Academy of Sciences	2014	188
Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers Siyuan Song, Tania Christova, Stephen Perusini, Cancer Research Tumor BiologySignaling PathwayIron ChelationIron Metabolismβ-Catenin Signaling	2011	161
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5 Guillermo Senisterra, Hong Wu, Abdellah Allali‐Hassani, Biochemical Journal	2012	158
Structure and mechanism of action of the hydroxy–aryl–aldehyde class of IRE1 endoribonuclease inhibitors Mário Sanches, Nicole M. Duffy, Manisha Talukdar, Nature Communications Molecular PharmacologyAldehyde DehydrogenaseBiochemistryMedicineNatural Sciences	2014	130
Functional characterization of a PROTAC directed against BRAF mutant V600E Ganna Posternak, Xiaojing Tang, Pierre Maisonneuve, Nature Chemical Biology Natural SciencesProtein BiosynthesisBraf Mutant V600eMolecular BiologyProteomics	2020	127
Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma Sina Haftchenary, H. Artee Luchman, Andriana O. Jouk, ACS Medicinal Chemistry Letters High-grade GliomasTreating GlioblastomaCancer BiologyGliomaTumor Biology	2013	125

Page 1